discount acrobat 8 standard cheap microsoft office 2010 home and student buying microsoft office 2013 for mac purchase quicken 2005 buy microsoft frontpage software buy microsoft money 2007 deluxe buy microsoft office xp best buy dragon naturallyspeaking 10 preferred purchase autocad 2012 buying microsoft powerpoint 2003 buying quicken 2008 cheap windows server 2008 r2 paint shop pro x3 buy cost of 2008 windows server buy windows 7 code buying microsoft office 2010 as a student cheapest microsoft outlook 2003 used solidworks software for sale autocad lt 2012 cheap cheap ableton live 7 price of microsoft office 2007 home and student best price cs3 mac buy microsoft encarta 2009 premium discount wordperfect office x4 microsoft word for mac discount discount microsoft access 2003 software price of revit mep price of captivate 4 cheap illustrator cs3 rosetta stone english best buy

Strategy to conquer cancer drug resistance uncovered

Fri, Sep 9, 2011

Oral Cancer News

Author: staff

US scientists have identified a way in which cancer cells can become resistant to the cancer drug cetuximab (Erbitux), and suggest that treatments that are already available might be able to overcome this resistance. Researchers from the Dana-Farber Cancer Institute in Boston, US, have been studying why some patients only experience short-term benefits with cetuximab, or none at all.

Cetuximab is an antibody that interferes with cancer cell growth. It can be given in combination with chemotherapy to patients with bowel cancer or head and neck cancer. Until now, scientists didn’t know why some cancers failed to respond to the drug, or initially responded but then became resistant.

The new study, published in Science Translational Medicine, found that in some of the drug-resistant cells, a protein known as ErbB2 (also known as HER2/neu) was sending ‘grow’ signals. These were bypassing the ‘stop growing’ signals caused by the drug.

Pasi Janne, the study’s co-senior author, said: “ErbB2 activates a critical signalling pathway that is not normally blocked by cetuximab, and in this way subverts cetuximab’s function.

“Because ErbB2 isn’t affected by cetuximab, this is an easy way for cancers to become resistant to the drug.”

The researchers suggest that combining cetuximab with already available ErbB2 inhibitors such as trastuzumab (Herceptin) could produce an effective therapy to tackle cancers that previously showed resistance to cetuximab.

Henry Scowcroft, science information manager at Cancer Research UK, said: “Unfortunately, patients’s tumours can become resistant to treatment, and understanding why this happens is a major challenge in cancer research.

“This new study is a great example of how researchers are uncovering the molecular tricks cancer cells use to evade treatment, and finding out how to stop them doing so.

“Research like this gives us tremendous optimism that we’re on the cusp of a real revolution in cancer, although there’s a lot more work to do to make this a reality.”

Yonesaka, K. et al. (2011). Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab Science Translational Medicine, 3 (99), 99-99 DOI:10.1126/scitranslmed.3002442

Print Friendly
Be Sociable, Share!
, , , , , , ,

Leave a Reply

You must be logged in to post a comment.